ENZASTAURIN

Enzastaurin Adverse Events Reported to the FDA Over Time

How are Enzastaurin adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Enzastaurin, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Enzastaurin is flagged as the suspect drug causing the adverse event.

Most Common Enzastaurin Adverse Events Reported to the FDA

What are the most common Enzastaurin adverse events reported to the FDA?

Neutropenia	42 (4.28%)
Hypotension	38 (3.87%)
Fatigue	31 (3.16%)
Febrile Neutropenia	26 (2.65%)
Dehydration	25 (2.55%)
Anaemia	24 (2.44%)
Diarrhoea	24 (2.44%)
Pneumonia	23 (2.34%)
Abdominal Pain	21 (2.14%)
Dyspnoea	18 (1.83%)
Pleural Effusion	16 (1.63%)
	Show More
Sepsis	13 (1.32%)
Septic Shock	13 (1.32%)
Weight Decreased	13 (1.32%)
Nausea	12 (1.22%)
Acute Respiratory Distress Syndrome	11 (1.12%)
Dizziness	11 (1.12%)
Lobar Pneumonia	11 (1.12%)
Cardiomegaly	10 (1.02%)
Fall	10 (1.02%)
Ileus	10 (1.02%)
Intestinal Obstruction	10 (1.02%)
Intestinal Perforation	10 (1.02%)
Tachycardia	10 (1.02%)
Atelectasis	9 (.92%)
Convulsion	9 (.92%)
Oral Candidiasis	9 (.92%)
Pericardial Effusion	9 (.92%)
Platelet Count Decreased	9 (.92%)
Pulmonary Embolism	9 (.92%)
Supraventricular Tachycardia	9 (.92%)
Thrombocytopenia	9 (.92%)
Abdominal Abscess	8 (.81%)
Anorexia	8 (.81%)
Colonic Stenosis	8 (.81%)
Diverticulitis	8 (.81%)
Neutropenic Sepsis	8 (.81%)
Escherichia Infection	7 (.71%)
Haemoglobin Decreased	7 (.71%)
Heart Rate Increased	7 (.71%)
Pain	7 (.71%)
Aspartate Aminotransferase Increase...	6 (.61%)
Asthenia	6 (.61%)
Constipation	6 (.61%)
Death	6 (.61%)
Disease Progression	6 (.61%)
Hypokalaemia	6 (.61%)
Renal Failure	6 (.61%)
Renal Haemorrhage	6 (.61%)
Stomatitis	6 (.61%)
Urinary Tract Infection	6 (.61%)
Blood Creatinine Increased	5 (.51%)
Blood Potassium Decreased	5 (.51%)
Deep Vein Thrombosis	5 (.51%)
Femoral Neck Fracture	5 (.51%)
Gastrointestinal Necrosis	5 (.51%)
Hyperglycaemia	5 (.51%)
Hypocalcaemia	5 (.51%)
Hyponatraemia	5 (.51%)
Mucosal Inflammation	5 (.51%)
Multi-organ Failure	5 (.51%)
Peritonitis	5 (.51%)
Alanine Aminotransferase Increased	4 (.41%)
Arrhythmia	4 (.41%)
Back Pain	4 (.41%)
Cardiac Arrest	4 (.41%)
Decreased Appetite	4 (.41%)
General Physical Health Deteriorati...	4 (.41%)
Haematocrit Decreased	4 (.41%)
Infection	4 (.41%)
Muscular Weakness	4 (.41%)
Pancytopenia	4 (.41%)
Pyrexia	4 (.41%)
Thrombosis	4 (.41%)
Vomiting	4 (.41%)
Abdominal Pain Upper	3 (.31%)
Acute Myocardial Infarction	3 (.31%)
Blood Bilirubin Increased	3 (.31%)
Blood Sodium Decreased	3 (.31%)
Cardio-respiratory Arrest	3 (.31%)
Cerebrovascular Accident	3 (.31%)
Dysaesthesia	3 (.31%)
Haematemesis	3 (.31%)
Hepatic Enzyme Increased	3 (.31%)
Hypertension	3 (.31%)
Hypoaesthesia	3 (.31%)
Hypoaesthesia Oral	3 (.31%)
International Normalised Ratio Incr...	3 (.31%)
Leukopenia	3 (.31%)
Malaise	3 (.31%)
Malignant Neoplasm Progression	3 (.31%)
Melaena	3 (.31%)
Neuropathy Peripheral	3 (.31%)
Pneumocystis Jiroveci Pneumonia	3 (.31%)
Pulmonary Fibrosis	3 (.31%)
Renal Failure Acute	3 (.31%)
Respiratory Arrest	3 (.31%)
Sensory Loss	3 (.31%)
Trigger Finger	3 (.31%)
Urinary Retention	3 (.31%)
Abdominal Distension	2 (.2%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Enzastaurin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Enzastaurin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Enzastaurin

What are the most common Enzastaurin adverse events reported to the FDA?

Infections - Pathogen Unspecified	100 (10.18%)
White Blood Cell	73 (7.43%)
Gastrointestinal Signs	44 (4.48%)
Cardiac Arrhythmias	39 (3.97%)
Decreased And Nonspecific Blood Pre...	38 (3.87%)
Electrolyte And Fluid Balance Condi...	38 (3.87%)
Gastrointestinal Motility And Defec...	32 (3.26%)
Respiratory	31 (3.16%)
Neurological	29 (2.95%)
Anemias Nonhemolytic And Marrow Dep...	28 (2.85%)
Gastrointestinal Stenosis And Obstr...	28 (2.85%)
	Show More
Hematology Investigations	27 (2.75%)
Lower Respiratory Tract Disorders	27 (2.75%)
Pleural	18 (1.83%)
Renal Disorders	18 (1.83%)
Appetite And General Nutritional	17 (1.73%)
Hepatobiliary	16 (1.63%)
Injuries	15 (1.53%)
Gastrointestinal Ulceration And Per...	14 (1.43%)
Physical Examination Topics	14 (1.43%)
Fungal Infectious	13 (1.32%)
Bacterial Infectious	12 (1.22%)
Bone And Joint Injuries	12 (1.22%)
Embolism And Thrombosis	12 (1.22%)
Water, Electrolyte And Mineral	11 (1.12%)
Myocardial	10 (1.02%)
Pericardial	10 (1.02%)
Gastrointestinal Hemorrhages	9 (.92%)
Oral Soft Tissue Conditions	9 (.92%)
Platelet	9 (.92%)
Pulmonary Vascular	9 (.92%)
Seizures	9 (.92%)
Fatal Outcomes	8 (.81%)
Cardiac And Vascular Investigations	7 (.71%)
Gastrointestinal Vascular Condition...	6 (.61%)
Musculoskeletal And Connective Tiss...	6 (.61%)
Renal And Urinary Tract Investigati...	6 (.61%)
Bone, Calcium, Magnesium And Phosph...	5 (.51%)
Central Nervous System Vascular	5 (.51%)
Coronary Artery	5 (.51%)
Glucose Metabolism Disorders	5 (.51%)
Miscellaneous And Site Unspecified ...	5 (.51%)
Peritoneal And Retroperitoneal Cond...	5 (.51%)
Body Temperature Conditions	4 (.41%)
Hepatic And Hepatobiliary	4 (.41%)
Muscle	4 (.41%)
Peripheral Neuropathies	4 (.41%)
Urinary Tract Signs	4 (.41%)
Tendon, Ligament And Cartilage	3 (.31%)
Therapeutic And Nontherapeutic Effe...	3 (.31%)
Vascular Hypertensive	3 (.31%)
Cardiac Disorder Signs	2 (.2%)
Gastrointestinal	2 (.2%)
Gastrointestinal Inflammatory Condi...	2 (.2%)
Increased Intracranial Pressure And...	2 (.2%)
Leukemias	2 (.2%)
Lifestyle Issues	2 (.2%)
Microbiology And Serology	2 (.2%)
Neonatal And Perinatal Conditions	2 (.2%)
Nervous System Neoplasms Malignant ...	2 (.2%)
Skin Vascular Abnormalities	2 (.2%)
Sleep Disorders	2 (.2%)
Viral Infectious	2 (.2%)
Vision	2 (.2%)
Abdominal Hernias And Other Abdomin...	1 (.1%)
Acid-base	1 (.1%)
Adrenal Gland	1 (.1%)
Bronchial Disorders	1 (.1%)
Depressed Mood Disorders	1 (.1%)
Gallbladder	1 (.1%)
Gastrointestinal Conditions	1 (.1%)
Heart Failures	1 (.1%)
Lipid Metabolism	1 (.1%)
Medication Errors	1 (.1%)
Movement Disorders	1 (.1%)
Protein And Chemistry Analyses	1 (.1%)
Respiratory And Mediastinal Neoplas...	1 (.1%)
Skin And Subcutaneous Tissue	1 (.1%)
Spleen, Lymphatic And Reticulendoth...	1 (.1%)
Toxicology And Therapeutic Drug Mon...	1 (.1%)
Ureteric	1 (.1%)
Vascular	1 (.1%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Enzastaurin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Enzastaurin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.